Amgen and AstraZeneca's Asthma Drug Tezspire Shows Promise for Eosinophilic Esophagitis
Amgen (AMGN) and AstraZeneca’s (AZN) asthma therapy, Tezspire, has demonstrated success in a late-stage clinical trial targeting patients with eosinophilic esophagitis. This inflammatory disorder affects the esophagus and is marked by symptoms such as difficulty swallowing. The positive results suggest that Tezspire may have broader therapeutic applications beyond its current use for asthma. AstraZeneca announced these findings in a statement, highlighting potential new treatment options for patients with this rare condition.
Topics: asthma therapy clinical trials eosinophilic esophagitis pharmaceuticals